COO Cooper Companies (The)

Q3 2025 10-Q

Filed: Aug 28, 2025Period ending Jul 31, 2025

Health Care

Ophthalmic GoodsSEC EDGAR

Cooper Companies (The) (COO) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Aug 28, 2025 for the fiscal period ending Jul 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

• No newly added risk factors identified in this 10-Q versus most recent 10-K
• Competitive risk updated: CooperVision focusing on silicone hydrogel lenses and expanding single-use product franchises like clariti and MyDay amid shifting market modalities

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.1B

▲ +5.7% YoY▲ +5.8% QoQ

Net Income

$98M

▼ -6.1% YoY▲ +12.1% QoQ

Gross Margin

65.3%

▼ -85bp YoY▼ -249bp QoQ

Operating Margin

16.6%

▼ -263bp YoY▼ -187bp QoQ

Net Margin

9.3%

▼ -117bp YoY▲ +52bp QoQ

EPS (Diluted)

$0.49

▼ -5.8% YoY▲ +11.4% QoQ

Operating Cash Flow

$261M

▲ +26.0% YoY▲ +171.7% QoQ

Source: XBRL data from Cooper Companies (The) Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Cooper Companies (The) Quarterly Reports

Q1 2026 10-Q

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Cooper Companies (The)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.